Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 1,570 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control regimen Clear all
Terminated Phase 3 Interventional Results available

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

NCT02999854
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor, T-cell replete HSCT from a related, haploidentical donor
Biological · Drug · Procedure
Lead sponsor
Kiadis Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Nov 10, 2026, 1:12 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Placebo, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
39
States / cities
Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 10, 2026, 1:12 AM EST
Completed Not applicable Interventional

Deprescribing in Outpatient Internal Medicine Practices

NCT07226960
View directory record Official record
Conditions
Deprescribing
Interventions
medication review
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
75 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 10, 2026, 1:12 AM EST
Completed Not applicable Interventional

Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction

NCT02770313
View directory record Official record
Conditions
Intermittent Fasting
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
21 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Nov 10, 2026, 1:12 AM EST
Active, not recruiting Phase 3 Interventional

Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta

NCT05768854
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Bisphosphonate, Setrusumab
Drug · Biological
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
2 Years to 6 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 10, 2026, 1:12 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
navenibart, Placebo
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 10, 2026, 1:12 AM EST
Terminated Phase 3 Interventional

Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

NCT00282503
View directory record Official record
Conditions
Acute Graft-versus-Host Disease
Interventions
Methoxsalen+ECP, Methylprednisolone, Ecp
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Gainesville, Florida • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Nov 10, 2026, 1:12 AM EST
Terminated Phase 2 Interventional

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

NCT07037420
View directory record Official record
Conditions
Acromegaly
Interventions
ALXN2420, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Torrance, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 10, 2026, 1:12 AM EST
Completed Phase 3 Interventional Results available

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

NCT02929329
View directory record Official record
Conditions
Heart Failure
Interventions
Omecamtiv Mecarbil, Placebo, Standard of Care
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
8,256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
310
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 249 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Nov 10, 2026, 1:12 AM EST
Completed Phase 4 Interventional Results available

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

NCT02957682
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Praluent (Alirocumab), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
73
States / cities
Auburn, Alabama • Birmingham, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Nov 10, 2026, 1:12 AM EST
Completed Phase 1Phase 2 Interventional

Myeloma-Developing Regimens Using Genomics (MyDRUG)

NCT03732703
View directory record Official record
Conditions
Relapsed Refractory Multiple Myeloma
Interventions
Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide, Erdafitinib, dexamethasone, ixazomib, pomalidomide, Venetoclax, dexamethasone, ixazomib, pomalidomide, Daratumumab, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Selinexor, dexamethasone, ixazomib, pomalidomide
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Nov 10, 2026, 1:12 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Down Syndrome Memantine Follow-up Study

NCT02304302
View directory record Official record
Conditions
Down Syndrome, Intellectual Disability
Interventions
Memantine, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
15 Years to 32 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Nov 10, 2026, 1:12 AM EST
Completed Phase 2 Interventional Results available

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

NCT00550446
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Adalimumab, CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
22
States / cities
Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Nov 10, 2026, 1:12 AM EST
Completed Phase 3 Interventional

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

NCT01691846
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
aleglitazar+metformin, placebo+metformin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Nov 10, 2026, 1:12 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura

NCT00449540
View directory record Official record
Conditions
Migraine With Aura
Interventions
Active Transcranial Magnetic Stimulation (TMS) Device, Sham TMS Device
Device
Lead sponsor
Neuralieve
Industry
Eligibility
18 Years to 65 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Nov 10, 2026, 1:12 AM EST
Active, not recruiting Phase 4 Interventional Results available

IO Vancomycin in TSA

NCT05831774
View directory record Official record
Conditions
Shoulder Injuries
Interventions
Intervention - Intraosseous (IO) administration of vancomycin, Control - Standard IV administration of vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Nov 10, 2026, 1:12 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Levonorgestrel Intrauterine System For Emergency Contraception

NCT01539720
View directory record Official record
Conditions
Pregnancy, Unplanned, Pregnancy; Accident
Interventions
Ulipristal acetate, levonorgestrel IUS
Drug · Device
Lead sponsor
Planned Parenthood of the St. Louis Region and Southwest Missouri
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Nov 10, 2026, 1:12 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT02680574
View directory record Official record
Conditions
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
219
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 158 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Nov 10, 2026, 1:12 AM EST
Completed Not applicable Interventional

Intensive Discharge Intervention in Diabetes

NCT02122926
View directory record Official record
Conditions
Type II Diabetes, Cardiovascular Disease
Interventions
Intensive discharge intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Nov 10, 2026, 1:12 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Massage Therapy on QOL in Youth/Young Adults With Cystic Fibrosis

NCT01729585
View directory record Official record
Conditions
Cystic Fibrosis, Quality of Life
Interventions
Massage Therapy
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Nov 10, 2026, 1:12 AM EST
Withdrawn Not applicable Interventional

A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients

NCT03427008
View directory record Official record
Conditions
Medication Adherence, Transplant; Kidney
Interventions
mHealth Intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Nov 10, 2026, 1:12 AM EST
Terminated Phase 3 Interventional Results available

Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy

NCT00318474
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Mycophenolate Mofetil (MMF), MMF Placebo, ACEi, FOS
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
7 Years to 70 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Nov 10, 2026, 1:12 AM EST
Completed Phase 4 Interventional

Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma

NCT02577497
View directory record Official record
Conditions
Asthma
Interventions
beclomethasone, fluticasone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Nov 10, 2026, 1:12 AM EST
Terminated Phase 4 Interventional Results available

Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

NCT02531321
View directory record Official record
Conditions
Contraception, HIV
Interventions
Levonorgestrel and Ethinyl Estradiol
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Nov 10, 2026, 1:12 AM EST